Toggle navigation
Home
Search
Services
Blog
Contact
About
No. 73 a Phase Iia Cancer Prevention Trial of the Ppar/ Agonist Piogli-261015000
University of Minnesota Twin Cities, Minneapolis, MN, United States
Search grants from University of Minnesota Twin Cities
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Towards the Physiologic Function of MiRP-3
Treatment of Schizoaffective Disorder Using Mifepristone
Lactic Acidemia and Its Clinical Counterparts
Invariant T Cells and IL4 and Type I Diabetes
Biological Responses to Ozone Exposure
Recently added grants:
Project 5: Tumor Suppressor and Tumor Maintenance Genes
Core A: Administration
The role of neuroactive steroids in stress, drug craving and drug use in cocaine use disorders
Core B: Gene Modulation with RNAi and CRISPER
Digital treatments for opioids and other substance use disorders (DIGITS) in primary care: A hybrid type-III implementation trial
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
Division of Cancer Prevention And Control (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN015000-001
Application #
6994812
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2004
Total Cost
Indirect Cost
Institution
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Related projects
NIH 2006
N01 CN
No. 73 a Phase Iia Cancer Prevention Trial of the Ppar/ Agonist Piogli-261015000
/ University of Minnesota Twin Cities
NIH 2004
N01 CN
No. 73 a Phase Iia Cancer Prevention Trial of the Ppar/ Agonist Piogli-261015000
/ University of Minnesota Twin Cities
Publications
Rosas, R R; Cole, K A; Darrah, L et al.
(2012)
A comparison of screening methods in two early phase oral leukoplakia clinical trials.
Oral Dis 18:720-3
Comments
Be the first to comment on this grant